NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West Pharmaceutical” or the “Company”) (NYSE: WST) in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons and entities who purchased or otherwise acquired West Pharmaceutical securities between February 16, 2023, and February 12, 2025, both dates inclusive (the “Class Period”). Investors have until July 7, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The West Pharmaceutical class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West Pharmaceutical was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products portfolio; (ii) West Pharmaceutical’s SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to West Pharmaceutical’s profit margins due to operational inefficiencies; and (iii) these margin pressures created the risk of costly restructuring activities, including West Pharmaceutical’s exit from continuous glucose monitoring (“CGM”) contracts with long-standing customers.
The West Pharmaceutical class action lawsuit further alleges that on February 13, 2025, West Pharmaceutical issued its 2025 revenue forecast in the range of $2.88 billion to $2.91 billion, significantly below expectations. According to the complaint, West Pharmaceutical attributed the disappointing guidance in part to Contract Manufacturing headwinds, including the loss of two major CGM customers that had begun transitioning to in-house manufacturing of next-generation devices because West Pharmaceutical “made the decision to not participate going forward as our financial thresholds cannot be achieved.” The West Pharmaceutical class action lawsuit further alleges that West Pharmaceutical also revealed that its SmartDose wearable injector will become margin dilutive in 2025 due to lower pricing. On this news, the price of West Pharmaceutical’s stock fell more than 38%.
If you purchased or otherwise acquired West Pharmaceutical shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
